A 16-Week Study to Evaluate the Efficacy, Safety, and Tolerability of GLY-200 in Participants With Obesity

Status:
COMPLETED

Trial end date:
2024-10-23

Target enrollment:

Participant gender:

This study will evaluate the efficacy, safety, and tolerability of GLY-200 in participants with obesity.

PHASE2

Glyscend, Inc.